1993
Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa
Guttman M, Léger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM, Gjedde A. Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa. Movement Disorders 1993, 8: 298-304. PMID: 8341294, DOI: 10.1002/mds.870080308.Peer-Reviewed Original ResearchConceptsPositron emission tomographyNew COMT inhibitorL-DOPACOMT inhibitorsTreatment of patientsStriatal uptakeBrain uptakeBrain 6Cynomolgus monkeysParkinson's diseaseL-dopa analogEmission tomographyPromising agentSame animalsPET measurementsDiseaseMetabolismInhibitorsControl statePretreatmentPatientsFluorodopaAdjunctAdministrationUptake
1992
3‐O‐methyldopa administration does not alter fluorodopa transport into the brain
Guttman M, Léger G, Cedarbaum J, Reches A, Woodward W, Evans A, Diksic M, Gjedde A. 3‐O‐methyldopa administration does not alter fluorodopa transport into the brain. Annals Of Neurology 1992, 31: 638-643. PMID: 1514775, DOI: 10.1002/ana.410310611.Peer-Reviewed Original ResearchConceptsChronic L-DOPA therapyAdvanced Parkinson's diseaseL-dopa therapyPositron emission tomographic studiesL-DOPA administrationEmission tomographic studiesPositron emission tomographyL-dopa preparationsParkinsonian patientsPlasma concentrationsCynomolgus monkeysParkinson's diseasePatientsEmission tomographyL-DOPABrainTomographic studiesDiseaseAdministrationInfusionTherapyBlood
1991
Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys: Implications for the Treatment of Parkinson's Disease.
Cedarbaum J, Leger G, Guttman M. Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys: Implications for the Treatment of Parkinson's Disease. Clinical Neuropharmacology 1991, 14: 330. PMID: 1913700, DOI: 10.1097/00002826-199108000-00005.Peer-Reviewed Original Research
1990
Effect of Nitecapone (OR-462) on the Pharmacokinetics of Levodopa and 3-O-Methyldopa Formation in Cynomolgus Monkeys.
Cedarbaum JM, Léger G, Reches A, Guttman M. Effect of Nitecapone (OR-462) on the Pharmacokinetics of Levodopa and 3-O-Methyldopa Formation in Cynomolgus Monkeys. Clinical Neuropharmacology 1990, 13: 544. PMID: 2276119, DOI: 10.1097/00002826-199012000-00006.Peer-Reviewed Original ResearchConceptsCynomolgus monkeysEffect of nitecaponePeripheral COMT inhibitorSingle-dose studyPharmacokinetics of levodopaBlood-brain barrierConcentration-time curveLevodopa administrationPlasma pharmacokineticsCOMT inhibitorsAdverse physiological effectsFurther inhibitionLevodopaDoseNitecaponePhysiological effectsMonkeysPharmacokineticsNovel inhibitorsInhibitorsInhibitionCarbidopaAdministration